Genentech Returns Cancer Drug Rights to NewLink

16.06.2017 - US biotechnology group Genentech, part of Roche, is handing back rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod), an investigational cancer treatment. Genentech...